PMID: 11479431Aug 2, 2001

Functional role of melanoma inhibitory activity in regulating invasion and metastasis of malignant melanoma cells in vivo

Melanoma Research
A K BosserhoffR Buettner

Abstract

MIA (melanoma inhibitory activity) has been previously isolated from the tissue culture supernatant of melanoma cell lines as an autoregulatory activity, inhibiting thymidine incorporation. However, subsequent analyses of melanocytic tumours in vivo have correlated enhanced MIA expression with progression of melanocytic tumours, conflicting with the idea that MIA acts as a tumour suppressor. To investigate the role of MIA in vivo, we have therefore generated a panel of stably transfected B16 cell clones secreting different amounts of MIA. The capacity of these cell clones to form lung metastases in syngeneic C57Bl6 mice was strictly correlated to the level of MIA secretion, but the clones did not differ with respect to their proliferation in vitro. In summary, we suggest that MIA plays a causal role in promoting the metastasis of malignant melanomas, involving inhibition of tumour cell attachment to extracellular matrix molecules within their local milieu.

References

Dec 1, 1992·The Journal of Investigative Dermatology·G ScottJ B McCarthy
Jan 5, 1996·The Journal of Biological Chemistry·A K BosserhoffReinhard Buettner
Jun 1, 1996·Journal of Dermatological Science·F WachR Hein
Nov 24, 1999·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·M DeichmannH Näher
Oct 29, 2000·Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine·A JuergensenA K Bosserhoff

Citations

Sep 24, 2004·International Journal of Cancer. Journal International Du Cancer·Piotr JachimczakU Bogdahn
Jun 9, 2004·Gene Expression Patterns : GEP·A K BosserhoffReinhard Buettner
Apr 14, 2007·Cell Death and Differentiation·K KasunoK Irani
Feb 13, 2002·Molecular and Cellular Biology·Markus MoserReinhard Buettner
Feb 16, 2005·Cancer Cell International·Jamael El FitoriHelmut Friess
Nov 30, 2006·Biological Chemistry·Raphael StollAnja-Katrin Bosserhoff
Jun 13, 2009·International Journal of Cancer. Journal International Du Cancer·Jennifer Schmidt, Anja-Katrin Bosserhoff
Nov 29, 2005·International Journal of Experimental Pathology·Hai S DuongDiana V Messadi
Dec 12, 2012·Cancer·Petros D Grivas, Athanasios G Papavassiliou
Jan 22, 2010·International Journal of Cancer. Journal International Du Cancer·Sebastiano BattagliaMoray J Campbell
Mar 18, 2008·Developmental Biology·Sui LinJohn M Shannon
Oct 4, 2011·Mayo Clinic Proceedings·Shanique R PalmerSvetomir N Markovic
Oct 12, 2016·International Immunopharmacology·Joana FelixHélène Moins-Teisserenc
Oct 18, 2006·International Journal of Cancer. Journal International Du Cancer·Stephanie Arndt, Anja K Bosserhoff
Jun 23, 2004·Oncogene·Ina PoserAnja K Bosserhoff
Mar 22, 2019·Biochemistry and Cell Biology = Biochimie Et Biologie Cellulaire·Yu-Fei Wang, Jie Han
May 16, 2007·Clinical Science·Arantxa OrtegaAntonio J López-Farré
Jul 19, 2008·Radiographics : a Review Publication of the Radiological Society of North America, Inc·Venkateswar R SurabhiNeal C Dalrymple
May 19, 2005·Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico·Cristina Martínez ConesaMiguel Alcaraz Baños
Feb 15, 2003·The Journal of Biological Chemistry·Anja K BosserhoffClaus Hellerbrand
Mar 7, 2006·The Journal of Biological Chemistry·Richard BauerAnja-Katrin Bosserhoff
Nov 15, 2003·Laboratory Investigation; a Journal of Technical Methods and Pathology·Anja-Katrin BosserhoffTad A Holak
Jan 1, 2014·Experimental Dermatology·Alexander Riechers, Anja K Bosserhoff

Related Concepts

Mia1 protein, mouse
Cell Division Phases
Malignant Neoplasm of Lung
Melanoma
Mice, Inbred C57BL
Neoplasm Invasiveness
Neoplasm Proteins
Neoplasm Transplantation
Malignant Neoplasm of Skin
Transfection

Related Feeds

Antisense Oligonucleotides: ND

This feed focuses on antisense oligonucleotide therapies such as Inotersen, Nusinursen, and Patisiran, in neurodegenerative diseases including amyotrophic lateral sclerosis.